Pancreatic Adenocarcinoma

Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang, Keith Dredge

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 54; DOI: 10.1186/s40425-018-0363-5
Recent advances in adoptive cancer immunotherapy in china
Juhua Zhou

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P64; DOI: 10.1186/2051-1426-3-S2-P64
Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
Dung T Le, Todd S Crocenzi, Jennifer N Urum, Eric R Lutz, Daniel A Laheru, Elizabeth A Sugar, Robert H Vonderheide, George A Fisher, Andrew H Ko, Aimee L Murphy, Katherine McDougall, Sandy Ferber, Dirk G Brockstedt, Elizabeth M Jaffee

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P155; DOI: 10.1186/2051-1426-3-S2-P155
Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer
Androulla Elia, Louise Lincoln, Laura Rosa Brunet, Thorsten Hagemann

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P215; DOI: 10.1186/2051-1426-1-S1-P215

Main menu